Axsome Therapeutics has initiated the FORWARD Phase III trial evaluating AXS-14 for the management of fibromyalgia, with the ...

Intellia Therapeutics CEO John Leonard explained the circumstances of the patient death at the J.P. Morgan Healthcare ...

The FDA and EMA's joint guidance was created to ensure the pharmaceutical industry employs best practices when using AI in ...

Sanofi's amlitelimab has shown promise in the Phase III COAST 1 trial, but data from the COAST 2 study is yet to be announced ...

GSK will be filing for approval of bepirovirsen in hepatitis B to global regulatory authorities based on the Phase III data.

Anktiva plus checkpoint inhibitor therapy demonstrated statistically significant immune restoration across two clinical ...

NRG Therapeutics has dosed the first participants in its Phase I clinical trial of NRG5051, being developed as a ...

BioAge’s NLRP3 inhibitor has shown potential to reduce high-sensitivity C-reactive protein (hsCRP), a key marker of ...

An independent data monitoring committee has advised Akeso to submit a sNDA to the NMPA for cadonilimab’s approval in gastric ...

MRM Health has received clearance from the FDA for its IND application, enabling the company to start the STARFISH-UC Phase ...

In a paper published in Nature Scientific Reports, the UK Biobank was used to better understand how the risk of stroke is ...

The Mount Sinai TCC has introduced an AI clinical trial matching platform, PRISM, to improve access to cancer research ...